MEDICINOVA INC. - COMMON STOCK

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

11 Nov 2021 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting

10 Nov 2021 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology

03 Nov 2021 18:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)

21 Oct 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

02 Sep 2021 22:00:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

01 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

30 Aug 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Reports Second Quarter 2021 Financial Results and Business Update

12 Aug 2021 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease

06 Jul 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

29 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

28 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal

21 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in Maxim Group LLC Fireside Chat

14 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

07 Jun 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Reports First Quarter 2021 Financial Results and Business Update

13 May 2021 15:30:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

05 May 2021 19:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Gene Therapy Milestone Payments

22 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the B. Riley Neuroscience Conference

19 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova to Participate in the UBS Global Healthcare Virtual Conference

15 Apr 2021 05:30:00 By Nasdaq GlobeNewswire

MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

09 Mar 2021 15:00:00 By Nasdaq GlobeNewswire